SolasCure develops Aurase Wound Gel, an enzymatic debrider that eliminates slough and disrupts bacterial biofilm to prepare chronic wounds for healing. This technology addresses the persistent challenge of low healing rates in chronic wounds, impacting millions of patients globally.
Funding
$34.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IUFounders
Product
Problem
Chronic wounds affect millions worldwide, yet healing rates remain stubbornly low despite advancements in wound care. Current treatments often lack the ease of use and effectiveness needed to adequately debride chronic wounds, leading to prolonged patient suffering and a significant burden on healthcare systems.
Solution
SolasCure develops Aurase Wound Gel, an enzymatic debrider designed to prepare chronic wounds for healing. The gel aims to eliminate slough and disrupt bacterial biofilm, reducing bioburden and promoting a healthy wound bed. By addressing these key barriers to healing, Aurase Wound Gel offers a potential breakthrough therapeutic for patients with chronic wounds.
Target Audience
The primary target audience includes patients suffering from chronic wounds, as well as practitioners and healthcare systems seeking more effective debridement solutions.
Features
- Enzymatic debridement action to remove slough and necrotic tissue
- Biofilm disruption to reduce bacterial load in the wound
- Targeted action preserves healthy tissue
- Easy-to-use gel formulation for convenient application